Teva Points To Progress In Specialty Despite Headwinds For Copaxone
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Erez Vigodman declined to speak at length about Teva’s bid to acquire rival Mylan during the company’s quarterly call other than to say “we are prepared to devote all necessary resources to complete this combination.”